Archives of Clinical Infectious Diseases

Published by: Kowsar
Uncorrected Proof scheduled for 14 (2)

Interleukin-17A Genetic Polymorphisms as a Prognostic Markers for Resistence to Visceral Leishamniasis in the Iranian Population

Manoochehr Rasouli 1 , Elham Moazamian 2 , * , Mahboobeh Nasiri 3 , Maryam Keshavarz 1 and Sadaf Asaei 1
Authors Information
1 Immunology Departments, Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Microbiology, College of Sciences, Agriculture and Modern Technology, Shiraz Branch, Islamic Azad University, Shiraz, Iran
3 Department of Biology, Arsanjan Branch, Islamic Azad University, Arsanjan, Iran
Article information
  • Archives of Clinical Infectious Diseases: In Press (In Press); e57163
  • Published Online: March 16, 2019
  • Article Type: Research Article
  • Received: July 3, 2018
  • Revised: July 3, 2018
  • Accepted: August 12, 2018
  • DOI: 10.5812/archcid.57163

To Cite: Rasouli M, Moazamian E, Nasiri M, Keshavarz M, Asaei S. Interleukin-17A Genetic Polymorphisms as a Prognostic Markers for Resistence to Visceral Leishamniasis in the Iranian Population, Arch Clin Infect Dis. Online ahead of Print ; In Press(In Press):e57163. doi: 10.5812/archcid.57163.

Abstract
Copyright © 2019, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Ready PD. Epidemiology of visceral leishmaniasis. Clin Epidemiol. 2014;6:147-54. doi: 10.2147/CLEP.S44267. [PubMed: 24833919]. [PubMed Central: PMC4014360].
  • 2. Mohebali M. Visceral leishmaniasis in Iran: Review of the epidemiological and clinical features. Iran J Parasitol. 2013;8(3):348-58. [PubMed: 24454426]. [PubMed Central: PMC3887234].
  • 3. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, et al. The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis. J Clin Immunol. 2008;28(1):44-9. doi: 10.1007/s10875-007-9125-8. [PubMed: 17828618].
  • 4. Bacellar O, Faria D, Nascimento M, Cardoso TM, Gollob KJ, Dutra WO, et al. Interleukin 17 production among patients with American cutaneous leishmaniasis. J Infect Dis. 2009;200(1):75-8. doi: 10.1086/599380. [PubMed: 19476435]. [PubMed Central: PMC2732405].
  • 5. Carvalho EM, Barral-Netto M, Barral A, Broskyn CI, Bacellar O. Immunoregulation in leishmaniasis. Ciênc cult (Säo Paulo). 1994;46(5/6):441-5.
  • 6. Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol. 1998;161(1):409-14. [PubMed: 9647250].
  • 7. Chen J, Deng Y, Zhao J, Luo Z, Peng W, Yang J, et al. The polymorphism of IL-17 G-152A was associated with childhood asthma and bacterial colonization of the hypopharynx in bronchiolitis. J Clin Immunol. 2010;30(4):539-45. doi: 10.1007/s10875-010-9391-8. [PubMed: 20437253].
  • 8. Elshafie AI, Hlin E, Hakansson LD, Elghazali G, Safi SH, Ronnelid J, et al. Activity and turnover of eosinophil and neutrophil granulocytes are altered in visceral leishmaniasis. Int J Parasitol. 2011;41(3-4):463-9. doi: 10.1016/j.ijpara.2010.11.005. [PubMed: 21172349].
  • 9. Espinoza JL, Takami A, Nakata K, Onizuka M, Kawase T, Akiyama H, et al. A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. PLoS One. 2011;6(10). e26229. doi: 10.1371/journal.pone.0026229. [PubMed: 22028838]. [PubMed Central: PMC3197629].
  • 10. Kim SW, Kim ES, Moon CM, Park JJ, Kim TI, Kim WH, et al. Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease. Gut. 2011;60(11):1527-36. doi: 10.1136/gut.2011.238477. [PubMed: 21672939].
  • 11. Kleinschek MA, Muller U, Brodie SJ, Stenzel W, Kohler G, Blumenschein WM, et al. IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J Immunol. 2006;176(2):1098-106. doi: 10.4049/jimmunol.176.2.1098. [PubMed: 16393998].
  • 12. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity. 2004;21(4):467-76. doi: 10.1016/j.immuni.2004.08.018. [PubMed: 15485625].
  • 13. Lopez Kostka S, Dinges S, Griewank K, Iwakura Y, Udey MC, von Stebut E. IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J Immunol. 2009;182(5):3039-46. doi: 10.4049/jimmunol.0713598. [PubMed: 19234200]. [PubMed Central: PMC2658650].
  • 14. Matsuzaki G, Umemura M. Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol Immunol. 2007;51(12):1139-47. doi: 10.1111/j.1348-0421.2007.tb04008.x. [PubMed: 18094532].
  • 15. Nordang GB, Viken MK, Hollis-Moffatt JE, Merriman TR, Forre OT, Helgetveit K, et al. Association analysis of the interleukin 17A gene in Caucasian rheumatoid arthritis patients from Norway and New Zealand. Rheumatology (Oxford). 2009;48(4):367-70. doi: 10.1093/rheumatology/ken512. [PubMed: 19208686].
  • 16. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: Mechanisms of interleukin-17 function in disease. Immunology. 2010;129(3):311-21. doi: 10.1111/j.1365-2567.2009.03240.x. [PubMed: 20409152]. [PubMed Central: PMC2826676].
  • 17. O'Quinn DB, Palmer MT, Lee YK, Weaver CT. Emergence of the Th17 pathway and its role in host defense. Adv Immunol. 2008;99:115-63. doi: 10.1016/S0065-2776(08)00605-6. [PubMed: 19117534].
  • 18. Peters W, Killick-kendrick R. He leishmaniases in biology and medicine. Parasitology. 2009;96(3). doi: 10.1017/S0031182000080264.
  • 19. Pitta MG, Romano A, Cabantous S, Henri S, Hammad A, Kouriba B, et al. IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J Clin Invest. 2009;119(8):2379-87. doi: 10.1172/JCI38813. [PubMed: 19620772]. [PubMed Central: PMC2719936].
  • 20. Rasouli M, Keshavarz M, Kalani M, Moravej A, Kiany S, Badiee P. Toll-like receptor 4 (TLR4) polymorphisms in Iranian patients with visceral leishmaniasis. Mol Biol Rep. 2012;39(12):10795-802. doi: 10.1007/s11033-012-1973-5. [PubMed: 23053976].
  • 21. Rasouli M, Asaei S, Kalani M, Kiany S, Moravej A. Interleukin-17A genetic variants can confer resistance to brucellosis in Iranian population. Cytokine. 2013;61(1):297-303. doi: 10.1016/j.cyto.2012.10.012. [PubMed: 23131423].
  • 22. Saha S, Mondal S, Banerjee A, Ghose J, Bhowmick S, Ali N. Immune responses in kala-azar. Indian J Med Res. 2006;123(3):245-66. [PubMed: 16778308].
  • 23. Scriba TJ, Kalsdorf B, Abrahams DA, Isaacs F, Hofmeister J, Black G, et al. Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol. 2008;180(3):1962-70. doi: 10.4049/jimmunol.180.3.1962. [PubMed: 18209095]. [PubMed Central: PMC2219462].
  • 24. van de Veerdonk FL, Gresnigt MS, Kullberg BJ, van der Meer JW, Joosten LA, Netea MG. Th17 responses and host defense against microorganisms: An overview. BMB Rep. 2009;42(12):776-87. doi: 10.5483/BMBRep.2009.42.12.776. [PubMed: 20044948].
  • 25. Vargas-Inchaustegui DA, Xin L, Soong L. Leishmania braziliensis infection induces dendritic cell activation, ISG15 transcription, and the generation of protective immune responses. J Immunol. 2008;180(11):7537-45. doi: 10.4049/jimmunol.180.11.7537. [PubMed: 18490754]. [PubMed Central: PMC2641013].
  • 26. Wang JY, Shyur SD, Wang WH, Liou YH, Lin CG, Wu YJ, et al. The polymorphisms of interleukin 17A (IL17A) gene and its association with pediatric asthma in Taiwanese population. Allergy. 2009;64(7):1056-60. doi: 10.1111/j.1398-9995.2009.01950.x. [PubMed: 19210369].
  • 27. Zrioual S, Ecochard R, Tournadre A, Lenief V, Cazalis MA, Miossec P. Genome-wide comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol. 2009;182(5):3112-20. doi: 10.4049/jimmunol.0801967. [PubMed: 19234208].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments